Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs VanEck Video Gaming and eSports ETF (ESPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs VanEck Video Gaming and eSports ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $360.52 (market cap $9.43B), while VanEck Video Gaming and eSports ETF trades at $97.96. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| BIO | ESPO | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Sector/Thematic |
52-Week High | $356.25 | $122.30 |
52-Week Low | $241.71 | $85.25 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
ESPO trades at $97.98, down 1.63% today, with technical indicators showing a bullish bias as moving averages and oscillators signal buying opportunities. The stock shows strong momentum with ADX readings indicating a trending market. Support levels are established at $96, $97, and $98, while resistance sits at $100, $101, and $102.
The bullish technical setup suggests potential upside toward resistance levels, though fundamental analysis is limited due to unavailable financial ratios. Investors should monitor upcoming earnings reports for revenue growth and profitability metrics to validate the technical strength with fundamental support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →
